Our laboratory at the Hannover Medical School develops immunotherapies against cancer and for curing chronic immune diseases (www.stripecke-mhh.de ). We have developed chimeric antigen receptor T cells (CAR T cells) that kill cancer cells infected with Epstein-Barr Virus (EBV). The CRISPR / Cas9 gene editing technique is used to make EBV-CAR T cells more effective, safer and more widely clinically usable. The gene-edited EBV-CAR T cells will be tested pre-clinically in vitro and in vivo. The clinical development of EBV-CAR-T cells against lymphomas is a cooperation with the University of Dresden.
We offer
- The latest state of the art in multidisciplinary and international teams and laboratories
- Training in biotechnology and in preclinical research
- Fixed term position from June 1st, 2021 until May 31st , 2024
- The remuneration of the doctoral position is according to TV-L (65% E13)
The MHH offers a collegial introduction and diverse training and development opportunities as well as an extensive health program for employees. There is also a wide range of family support and a day-care center with emergency childcare. In addition, the usual social services of the public service are offered. The MHH is a certified family-friendly university and is committed to promoting women in professional life. Applications from women are particularly welcome. Severely disabled applicants will be given preference if they have the same qualifications.
Requirements
- Completed university degree (Master‘s Degree) in the field of biomedicine, biology, biochemistry or veterinary medicine.
- Strong interest in interdisciplinary cooperations for a doctorate (“Dr. rer. nat.” or PhD).
- Very good knowledge and practical experience in the field of molecular biology (CRISPR / Cas, vectors), immunology (cell culture, FACS, ELISA) and mouse models.
- MS Office application programs, FlowJo, GraphPad Prism, very good knowledge of English.
